Elicera Therapeutics AB Logo

Elicera Therapeutics AB

Develops CAR T-cell & oncolytic virus therapies for cancer, enhanced by its iTANK platform.

ELIC | ST

Overview

Corporate Details

ISIN(s):
SE0015382080 (+1 more)
LEI:
549300I35L0R4INBFG27
Country:
Sweden
Address:
C/O Elicera Therapeutics AB, 402 24 Göteborg
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Elicera Therapeutics AB is a clinical-stage immuno-oncology company that develops cell and gene therapies for immune-based cancer treatments. The company's work focuses on two core technology areas: oncolytic viruses and Chimeric Antigen Receptor (CAR) T-cell therapies. Elicera's key asset is the proprietary iTANK (Immuno-Oncology Targeting and Killing) technology platform, a universal solution designed to enhance the efficacy of any CAR T-cell therapy by enabling a multi-targeted immune attack, particularly against solid tumors. The company's pipeline includes four drug candidates, with its oncolytic virus (ELC-100) and CAR T-cell therapy (ELC-301) in or entering clinical phase I/II trials for neuroendocrine tumors and B-cell lymphoma, respectively.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Elicera Therapeutics AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Elicera Therapeutics AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-03-11 Margareth Jorvid Other Other 21,700 40,145.00 SEK

Peer Companies

Company Country Ticker View
Daebonglsco.,Ltd Logo
Develops raw materials and APIs for the personal care, pharmaceutical, and food industries.
South Korea 078140
DaehanPharmaceutical Logo
Develops and manufactures pharmaceuticals and health foods for human and animal markets worldwide.
South Korea 023910
Daesung Microbiological Labs. Co. Ltd Logo
Researches and manufactures veterinary vaccines and medicines for livestock, fish, and canines.
South Korea 036480
DAEWOONG PHARMA Logo
A global R&D partner for drug development, manufacturing, and commercialization services.
South Korea 069620
DAIICHI SANKYO COMPANY, LIMITED Logo
A global pharmaceutical firm developing novel therapies with a focus on oncology and ADCs.
Japan 4568
Daito Pharmaceutical Co., Ltd. Logo
Manufactures APIs, generic drugs, and health foods; provides contract manufacturing services.
Japan 4577
D&D Pharmatech Inc. Logo
Develops oral & injectable peptide therapies for metabolic & chronic diseases like obesity.
South Korea 347850
Dechra Pharmaceuticals PLC Logo
Develops & sells veterinary pharmaceuticals for companion animals, exclusively to veterinarians.
United Kingdom DPH
Dermapharm Holding SE Logo
Manufactures patent-free branded pharmaceuticals & healthcare products for niche markets.
Germany DMP
Deutsche Biotech Innovativ AG Logo
Develops biomarker-driven therapeutics and diagnostics for serious diseases with unmet needs.
Germany DBI

Talk to a Data Expert

Have a question? We'll get back to you promptly.